Questionnaire/CRF | Description of time points for completion | Baseline | 3Â weeks | 6Â weeks | 9Â weeks | 12Â weeks | 18Â weeks | 24Â weeks |
---|---|---|---|---|---|---|---|---|
Consent form | Baseline | X | Â | Â | Â | Â | Â | Â |
Baseline: patient sociodemographic data form | Baseline | X | Â | Â | Â | Â | Â | Â |
Baseline: computer usage questionnaire | Baseline | X | Â | Â | Â | Â | Â | Â |
Patient-reported eRAPID symptom questionnaire (eRAPID intervention arm only) | Within 24Â h of study entry and weekly during treatment and 6Â weeks afterwards (12Â weeks total). Then at 18 and 24Â weeks. | X weekly | X weekly | X weekly | X weekly | X weekly | X (except rectal) | X (except rectal) |
Patient Outcome Measures  FACT-G  EORTC-QLQ-C30  EQ-5D-5 L | Baseline, 6, 12 and 24 weeks | X |  | X |  | X |  | X |
 Self-efficacy, Lorig 6-item | Baseline and 12 weeks | X |  |  |  | X |  |  |
 Patient Activation Measure (PAM) | Baseline and 12 weeks | X |  |  |  | X |  |  |
 Use of resources form | 6, 12 and 24 weeks |  |  | X |  | X |  | X |
 System Usability Scale | 24 weeks (eRAPID intervention arm only) |  |  |  |  |  |  | X |
Participant withdrawal feedback form | At point of withdrawal | Â | Â | Â | Â | Â | Â | Â |
End of study patient questionnaire | 24Â weeks | Â | Â | Â | Â | Â | Â | X |
Clinician questionnaires | ||||||||
 Clinician eRAPID feedback form (eRAPID intervention arm only) | At routine hospital appointments throughout the study |  | X | X | X | X | X (except rectal) | X (except rectal) |
 Clinician record of CTCAE | To be completed by clinician at the follow-up appointment 4–6 weeks after completion of treatment (exact time-point will be different for different disease groups) |  |  |  |  |  |  |  |